Pharmacy

Sun Pharmaceutical Industries Ltd, recently announced that US Food ' and Drug Administration (USFDA) has granted its US subsidiary an approval to market a generic version of sumatriptan succinate injection. This is the first Abbreviated New Drug Application (ANDA) approval for a sumatriptan auto injector.

The pharmaceutical company has got the permission to market - this injection in strength of 6 mg (base)/0.5 m. Annual sale for sumatriptan succinate injections in the US is approximately $190 million. Sumatriptan succinate injection is indicated for the acute treatment of migraine attacks with or without aura and the acute treatment of cluster headache episodes.

This generic injection packaged in a single-dose syringe with auto injector is equivalent to Imitrex9 STAT dose System, 6 mg (base) 0.5 mL of GlaxoSmithKline.